CN116171161A - 用pcsk9和ldlr调节剂治疗败血症 - Google Patents

用pcsk9和ldlr调节剂治疗败血症 Download PDF

Info

Publication number
CN116171161A
CN116171161A CN202180062771.1A CN202180062771A CN116171161A CN 116171161 A CN116171161 A CN 116171161A CN 202180062771 A CN202180062771 A CN 202180062771A CN 116171161 A CN116171161 A CN 116171161A
Authority
CN
China
Prior art keywords
seq
nucleic acid
pcsk9
acid molecule
ldlr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180062771.1A
Other languages
English (en)
Chinese (zh)
Inventor
J·霍罗威茨
L·A·洛塔
M·A·R·费雷拉
A·达马斯克
C·波尔丁
G·曼维莲
M·康托尔
A·巴拉斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CN116171161A publication Critical patent/CN116171161A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180062771.1A 2020-08-25 2021-08-25 用pcsk9和ldlr调节剂治疗败血症 Pending CN116171161A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063069789P 2020-08-25 2020-08-25
US63/069,789 2020-08-25
PCT/US2021/047502 WO2022046873A1 (en) 2020-08-25 2021-08-25 Treatment of sepsis with pcsk9 and ldlr modulators

Publications (1)

Publication Number Publication Date
CN116171161A true CN116171161A (zh) 2023-05-26

Family

ID=77775030

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180062771.1A Pending CN116171161A (zh) 2020-08-25 2021-08-25 用pcsk9和ldlr调节剂治疗败血症

Country Status (10)

Country Link
US (2) US12378557B2 (https=)
EP (1) EP4204563A1 (https=)
JP (2) JP2023539742A (https=)
KR (1) KR20230057410A (https=)
CN (1) CN116171161A (https=)
AU (1) AU2021335200A1 (https=)
CA (1) CA3191030A1 (https=)
IL (1) IL300439A (https=)
MX (1) MX2023001912A (https=)
WO (1) WO2022046873A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119716057A (zh) * 2024-12-10 2025-03-28 中国人民解放军总医院 Pcsk6在诊断脓毒症中的应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2634837A (en) 2022-06-07 2025-04-23 Scribe Therapeutics Inc Compositions and methods for the targeting of PCSK9

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1471152A1 (en) 2003-04-25 2004-10-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutations in the human PCSK9 gene associated to hypercholesterolemia
KR100985090B1 (ko) 2008-05-23 2010-10-04 한국과학기술연구원 크라이센 노출 여부 확인용 바이오마커 및 이를 이용한확인 방법
JP5703218B2 (ja) 2008-08-14 2015-04-15 ネステク ソシエテ アノニム 満腹感、脂質代謝及び脂肪利用に影響を及ぼすための組成物及び方法
EP2488663A4 (en) 2009-10-16 2012-09-05 Genetics Invest Pty Ltd SENSITIVITY TO MACRONUTRIENT
WO2012048414A1 (en) 2010-10-12 2012-04-19 Mcmaster University A method of regulating plasma lipoproteins
WO2013043041A2 (en) 2011-09-21 2013-03-28 Infovalley® Group Of Companies Methods and compositions for diagnosing familial hypercholesterolemia
US20150140005A1 (en) * 2012-05-17 2015-05-21 Cyon Therapeutics Inc. Methods and Uses for Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors
WO2014028946A2 (en) 2012-08-17 2014-02-20 The Broad Institute, Inc. Modulators of hepatic lipoprotein metabolism
TWI682780B (zh) 2013-05-30 2020-01-21 美商再生元醫藥公司 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
EP3052521A1 (en) * 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015073709A2 (en) 2013-11-14 2015-05-21 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Detection of atherosclerotic cardiovascular disease risk and heart failure risk
WO2015073710A2 (en) 2013-11-14 2015-05-21 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES Detection of atherosclerotic cardiovascular disease risk and myocardial infarction risk
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
WO2015092393A2 (en) 2013-12-17 2015-06-25 Kymab Limited Human targets
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
CA2947127A1 (en) 2014-05-02 2015-11-19 Cerenis Therapeutics Holding Sa Hdl therapy markers
EP4328245A3 (en) 2014-07-15 2024-06-05 Kymab Ltd. Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
WO2016023916A1 (en) 2014-08-12 2016-02-18 Kymab Limited Treatment of disease using ligand binding to targets of interest
WO2016071701A1 (en) 2014-11-07 2016-05-12 Kymab Limited Treatment of disease using ligand binding to targets of interest
NL2014136B1 (en) 2015-01-14 2017-01-27 Stichting Katholieke Univ Annexin A2 SNP and von Willebrand Disease.
US10265379B2 (en) 2015-09-16 2019-04-23 Annabelle Rodriguez Oquendo Use of recombinant lymphocyte activation gene-3 as a companion therapeutic for patients at risk for cardiovascular disease and other chronic inflammatory diseases
WO2017218798A1 (en) 2016-06-15 2017-12-21 Boston Heart Diagnostics Systems and methods for diagnosing familial hypercholesterolemia
ES2871783T3 (es) * 2016-09-20 2021-11-02 Univ Aarhus Compuestos para el tratamiento de trastornos del metabolismo de las lipoproteínas
US10337070B2 (en) 2017-01-12 2019-07-02 Cardioforecast Ltd. Methods and kits for treating cardiovascular disease
US20190345557A1 (en) 2017-07-12 2019-11-14 The General Hospital Corporation Atrial fibrillation polygenic risk score
US20190017119A1 (en) 2017-07-12 2019-01-17 The General Hospital Corporation Genetic Risk Predictor
US20190341125A1 (en) 2017-07-12 2019-11-07 The General Hospital Corporation Inflammatory bowel disease polygenic risk score
US20190330698A1 (en) 2017-07-12 2019-10-31 The General Hospital Corporation Diabetes polygenic risk score
US20190345566A1 (en) 2017-07-12 2019-11-14 The General Hospital Corporation Cancer polygenic risk score
US11680296B2 (en) 2017-10-16 2023-06-20 Massachusetts Institute Of Technology Mycobacterium tuberculosis host-pathogen interaction
WO2019199684A1 (en) 2018-04-09 2019-10-17 The Regents Of The University Of Michigan Methods and systems for biocellular marker detection and diagnosis using a microfluidic profiling device
MX2020013994A (es) 2018-06-22 2021-05-27 Bluestar Genomics Inc Análisis de hidroximetilación de muestras de ácido nucleico sin células para asignación de tejido de origen, y métodos relacionados de uso.
US20210285050A1 (en) 2018-07-06 2021-09-16 United States Government As Represented By The Department Of Veterans Affairs Pde3b variants
WO2020010186A1 (en) * 2018-07-06 2020-01-09 Derek Klarin Pcsk9 variants
JP2022507958A (ja) * 2018-11-27 2022-01-18 ノバルティス アーゲー 代謝障害の治療用のプロタンパク質転換酵素サブチリシン／ケキシン９型（ｐｃｓｋ９）阻害薬としての環状四量体化合物
EP3969620B1 (en) 2019-05-17 2025-06-25 Regeneron Pharmaceuticals, Inc. Genome-based methods for reducing cardiovascular risk
CN113874020A (zh) 2019-05-22 2021-12-31 基诺富公司 使用曲美替尼和标志物治疗神经退化性疾病的给药方法和剂量方案
US20200368239A1 (en) 2019-05-22 2020-11-26 Genuv Inc. Treatment of amyotrophic lateral sclerosis using trametinib
WO2021058597A1 (en) 2019-09-24 2021-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of determining whether a subject is at risk of developing arterial plaques
US20210113536A1 (en) 2019-10-21 2021-04-22 United States Government as Represented by the Department of Veteran Affairs Methods and compositions for detecting and treating venous thromboembolism

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119716057A (zh) * 2024-12-10 2025-03-28 中国人民解放军总医院 Pcsk6在诊断脓毒症中的应用
CN119716057B (zh) * 2024-12-10 2025-07-15 中国人民解放军总医院 Pcsk6在诊断脓毒症中的应用

Also Published As

Publication number Publication date
IL300439A (en) 2023-04-01
WO2022046873A1 (en) 2022-03-03
KR20230057410A (ko) 2023-04-28
US20260078378A1 (en) 2026-03-19
AU2021335200A9 (en) 2024-10-03
JP2023539742A (ja) 2023-09-19
EP4204563A1 (en) 2023-07-05
JP2026004359A (ja) 2026-01-14
US12378557B2 (en) 2025-08-05
US20220064652A1 (en) 2022-03-03
AU2021335200A1 (en) 2023-04-27
MX2023001912A (es) 2023-07-10
CA3191030A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
AU2020250262B2 (en) Compositions for modulating tau expression
RU2751847C9 (ru) Модуляция экспрессии гентингтина
KR102585973B1 (ko) 타우 발현을 조절하기 위한 올리고뉴클레오티드
KR20220112290A (ko) 안지오포이에틴 유사 4(angptl4) 관련 질환의 치료를 위한 올리고뉴클레오타이드
CN116171161A (zh) 用pcsk9和ldlr调节剂治疗败血症
CN115362255A (zh) 用无七之子2(sos2)抑制剂治疗眼科疾患
CN117795076A (zh) 用丝裂原活化蛋白激酶激酶激酶15(map3k15)抑制剂治疗代谢病症的方法
CN117836412A (zh) 用含环状结构跨膜蛋白1(kremen1)抑制剂治疗骨矿物质密度降低的方法
CN111278468A (zh) 用于脂肪营养不良的自体细胞疗法的人脂肪组织祖细胞
KR20190081158A (ko) Itpkc 및 slc11a1 유전자 다형성을 이용한 가와사키병 발병 예측 방법
CN116356008A (zh) 先天性心脏病相关setd2基因新发变异位点及其应用
CN113825839A (zh) 用固醇调节元件结合蛋白切割激活蛋白(scap)抑制剂治疗脂质水平升高
KR102724406B1 (ko) Psen1 돌연변이 세포 및 이의 이용
US20250283084A1 (en) Mapt antisense oligonucleotide
RU2823361C1 (ru) Композиции для модулирования экспрессии тау-белка
KR20130048240A (ko) Ｐｃｂｐ―１ 항원에 대한 모노클로날 항체, 및 그의 용도
CN115485394A (zh) 溶质载剂家族26成员5(slc26a5)变体及其用途
JP2002355069A (ja) 新規な遺伝的多型による慢性関節リウマチの検査方法
JP2003102483A (ja) アクチン脱重合因子・コフィリンを脱リン酸化する酵素を含む、ヒト由来の新規タンパク質およびその遺伝子

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination